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http://www.biomedcentral.com/1756-0500/7/42RESEARCH ARTICLE Open AccessGenetic variants conferring susceptibility to
Alzheimer’s disease in the general population; do
they also predispose to dementia in Down’s
syndrome
Ashok Patel1*, Simon D Rees2, M Ann Kelly2, Stephen C Bain3, Anthony H Barnett2,4, Anisha Prasher5,
Humaria Arshad6 and Vee P Prasher6,7Abstract
Background: Down’s syndrome (DS) is caused by either complete or partial triplication of chromosome 21,
affecting approximately 1/1000 live births, and it is widely accepted that individuals with DS are more likely to
develop dementia of Alzheimer’s disease (DAD) compared with the general population. Recent collaborative
genome-wide association studies of large case control data sets of individuals with and without Alzhemier’s disease
(AD) have revealed new risk variants for dementia, as well as confirming previously identified risk variants. In this
study, nine AD-derived SNPs, near or within the CR1 (rs3818361), BIN1 (rs744373), CD2AP (rs9349407), EPHA1
(rs11767557), CLU (rs1532278), MS4A6A/4A (rs610932), PICALM (rs561655), ABCA7 (rs3764650) and CD33 (rs3865444)
genes were genotyped in 295 individuals with DS.
Results: There were no significant associations between these nine GWAS-derived SNPs and DAD in British
Caucasian individuals with DS. Interestingly the CR1 rs3818361 variant appeared to be associated with mortality in
our cohort, particularly in the subjects without dementia. To our knowledge, this is the first time that this variant
has been implicated as a determinant of mortality and the finding warrants further investigation in other cohorts
with DS.
Conclusions: This study shows negative associations of nine AD-derived SNPs with DAD in DS. This may be due to
the modest size of our cohort, which may indicate that our study is insufficiently powered to pick up such
associations. We cannot conclusively exclude a role for these SNPs in DAD in DS. Clearly, efforts to investigate
genetic variants with small effects on disease risk require a much larger cohort of individuals with DS. In fact, we
hypothesize that a sample size of 4465 individuals with DS would be needed to determine the role in DAD in DS
of the nine AD-derived SNPs investigated in this study. We therefore recommend that all national and international
clinics with access to individuals with DS should contribute DNA samples to form DS consortia.
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Down’s syndrome (DS) is caused typically by a complete,
or occasionally partial, triplication of chromosome 21 and
has an incidence of approximately 1/1000 live births. The
phenotype is complex and variable, primarily characterised
by cognitive and language dysfunction coupled with sen-
sory and neuromotor deficits and a neuropathology result-
ing in decreased brain size and weight [1]. DS is also
characterised by congenital heart and bowel problems [2]
and increased mortality rates both in early and later stages
of life [3].
Evidence indicates that the dementia in DS is in fact
Alzheimer’s disease (AD) [4,5]. It is widely accepted that
individuals with DS are much more likely to develop
dementia of AD (DAD) than the general population,
especially over the age of 35 years, [6,7]. Virtually all
individuals with DS are likely to develop the neuro-
pathological changes characteristic of AD by the age of
40 years; these include deposits of extracellular beta-
amyloid in neuritic plaques and intracellular neurofib-
rillary tangles [8]. However, despite the nearly universal
occurrence of AD pathology by this age, it is clear that not
all of these individuals develop clinical psychopathology of
AD. A number of studies have shown that there is wide
variation in the age of onset of dementia, from 38 to
70 years, with an average age at onset between 50 and
55 years [9,10]. This variation may be explained by a
number of factors, including methodological difficulties
in diagnosis of DAD in this population [11], triplication
of the beta-amyloid precursor protein (APP) gene [12],
APOE genotypes [6,13], gender [14] and a number of
unknown genetic variants.
The neuropathological manifestations of DAD in DS
have been attributed to triplication and over-expression
of the APP gene located on chromosome 21 [12]. How-
ever, factors other than APP triplication must be respon-
sible for the individual differences in susceptibility to the
formation of fibrillised plaques and for the wide range in
age at onset of dementia [6]. In the general population the
gene coding for apolipoprotein E (APOE) on chromosome
19 has been shown to modulate the risk of AD in some
studies. The ε4 allele of APOE is associated with earlier
age at onset and increased risk of AD [15-19] whilst
the APOE ε2 allele may reduce the risk of dementia in
heterozygous carriers [20,21].
A number of studies have shown an association between
the APOE ε4 allele and an increased risk of DAD in indi-
viduals with DS [6,13,22,23], but other studies have shown
conflicting results [24-26]. There is evidence that APOE ε2
is associated with increased longevity in DS [27,28] and a
potential protective effect on DAD [28-30], but these effects
have not been confirmed by all studies [13,22,23]. Similarly,
the influence of the APOE ε4 allele on early mortality in
individuals with DS [13,31] is subject to dispute [32].A number of genes besides APOE have been implicated
in susceptibility to DAD in individuals with DS, including
TNF-α [24], BACE 1 [33], PSEN [34], SORL1 [35],
ALDH18A1 and RUNX1 [36].
Recent collaborative genome-wide association studies
of large case control data sets of individuals with AD
have revealed new risk variants for dementia, as well as
confirming previously identified risk variants [36,37].
Our present understanding of the genetic architecture of
AD suggests that at least ten loci contribute to disease
risk; APOE, CR1, CLU, PICALM, BIN1, EPHA1, MS4A,
CD33, CD2AP and ABCA7. As described above, the con-
tribution of APOE to predisposition to dementia in DS has
been widely studied [38], but the influence of the other
nine risk variants on the development of DAD has yet to
be investigated. The aim of our study, therefore, was to
characterise the contribution of these AD susceptibility
loci in the general population to the risk of DAD in a
cohort of individuals with DS, to determine whether the
two diseases have a common genetic basis.Methods
Participants
Three hundred and four adults with DS (16 years and
above) of white Caucasian ancestry, known to the local
clinical services and voluntary organizations, were re-
cruited into the study. Consent or assent was obtained
as was appropriate. All participants resided in the West
Midlands, United Kingdom. Ethical Committee approval
was obtained from the local authority with approval from
the NHS Trust.Procedures
A prospective cohort design was used, with a range of
two to 14 sequential assessments over the course of the
follow up. Approximately 80% of participants had cyto-
genetic tests. Of these, 222 had trisomy 21, 12 had tri-
somy 21 translocation, 7 had trisomy 21 mosaicism, 1
had partial trisomy 21 and 1 had trisomy 21 and 48XXY.
Some individuals did not consent to give blood for cyto-
genetic tests, or blood could not be obtained from them.
Baseline assessment included a standard full psychiatric
history and mental state examination. Mental disorders
were diagnosed using the ICD-10 Symptom Checklist
for Mental Disorders [39] according to ICD-10 research
criteria [40]. An ascertainment of severity of dementia
according to ICD-10 criteria [41] was made along with a
physical examination (including an assessment of hear-
ing and vision). There was also a comprehensive review
of medical records, haematological, biochemical, and
thyroid screening and a comprehensive review of all pre-
scribed medications. Participants diagnosed with mental
or physical disorders were treated appropriately and then
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http://www.biomedcentral.com/1756-0500/7/42followed up. Dementia in Alzheimer’s disease was deter-
mined according to ICD-10 research criteria [40].
SNP selection and genotyping
Nine SNPs that had previously been robustly associ-
ated with late-onset Alzheimer’s disease (p < 5 × 10-8)
were genotyped in 295 subjects with Down’s syndrome.
These SNPs were in or near the CR1 (rs3818361), BIN1
(rs744373), CD2AP (rs9349407), EPHA1 (rs11767557),
CLU (rs1532278), MS4A6A/4A (rs610932), PICALM
(rs561655), ABCA7 (rs3764650) and CD33 (rs3865444)
genes [37]. Genotyping was performed by KBioscience
(Hertfordshire, UK) using the KASP™ genotyping method
(www.lcggenomics.com/genotyping). The DNA samples
of 268 subjects, both with (N = 109) and without (N = 159)
dementia, demonstrated genotyping success rates greater
than 75% over the 9 SNPs and were included in the main
analyses. One hundred and twenty-five samples (47%)
were genotyped in duplicate for all SNPs. Genotypes
were called independently and an error rate of zero was
observed.
Statistical analyses
Cox proportional hazard regression was used to assess the
effect of each SNP on the risk of dementia and mortality,
including sex and level of intellectual disability as covari-
ates. Age of onset of dementia or age at last assessment,
or age at death or age at last assessment, were the time-to-
event variables. As the minimum age at onset of dementia
in the study was 38 years, only those non-demented sub-
jects who were = > 38 years of age at last assessment were
included in the risk of DAD in DS analyses (Ntotal = 225).
The earliest age of death was 36 years, therefore only
those surviving subjects who were = > 36 years of age at
last assessment were included in the mortality risk ana-
lysis (Ntotal = 233). Mortality risk was estimated both in
the entire cohort and within the subset of individuals
who remained non-demented throughout the period of
the study. SNPs were analysed using an additive model,
coding each genotype as 0, 1 or 2 Alzheimer’s disease
risk alleles. The single Hazard Ratio (HR) given for each
SNP therefore represents a per risk allele effect.
For the risk of DAD in DS analyses (Nevent = 109), given
minor allele frequencies of between 5–50%, this study had
80% power to detect HRs in the region of 3.43–1.71. Re-
spective estimates for the mortality analyses (Nevent = 80),
given the same allele frequencies, were 4.21–1.87. Given
the modest effect sizes of the studied SNPs on the risk of
Alzheimer’s disease (reported odds ratios of 1.1-1.23
[36,37]), it was unlikely that adequate statistical power
could be achieved for the analysis of individual SNPs in
DAD using the current study’s modest sample size. We
therefore created a genetic risk score (GRS), calculated as
the total number of Alzheimer’s disease risk alleles withineach individual, using those subjects with a 100% geno-
typing success rate (N = 243). The GRS was used to in-
vestigate whether genetic susceptibility for Alzheimer’s
disease in the general population overlapped with that
for DAD in DS. All DAD in DS analyses were adjusted
for APOE using SNP rs429358 as a proxy. Throughout
this manuscript associations are referred to as nominally
significant (p < 0.05) or study-wide significant (corrected
for the 9 independent SNPs; p < 5.5 × 10-3). All analyses
were conducted using R (www.R-project.org) or STATA
IC V10.1 (Stata Corporation, College Station, TX, USA).
Results
DAD in DS
One SNP was nominally associated with the development
of DAD in DS; the PICALM rs561655 variant appeared to
reduce the risk of DAD (HR = 0.72, p = 0.02; Table 1). In
contrast, six of the nine variants had hazard ratios greater
than 1, although none of these was significantly associ-
ated with the development of dementia (Table 1). The
combined GRS was not associated with DAD in DS
(HR = 0.98, p = 0.78; Table 1).
Mortality
In the overall cohort, the PICALM rs561655 variant was
nominally associated with a reduced risk of mortality
(HR = 0.71, p = 0.048) whilst the CR1 rs3818361 variant
increased the risk of early mortality (HR = 1.65, p =
5.36 × 10-3) (Table 2); this latter association achieved
study-wide significance. In the non-demented group,
the effect of the CR1 variant was more pronounced
(HR = 2.33, p = 4.08 × 10-3), whilst that of the PICALM
SNP disappeared. Variants in or near CD33 and CD2AP
also demonstrated weak but nominally significant asso-
ciations with mortality (Table 2).
The GRS was not significantly associated with mortality
in either the overall cohort or the non-demented subset
(Table 2).
Discussion
To our knowledge, this is first study to investigate the ef-
fects of nine of the GWAS-derived susceptibility variants
for Alzheimer’s disease in the general population on the
development of DAD in DS. The CR1 (rs3818361), BIN1
(rs744373), CD2AP (rs9349407), EPHA1 (rs11767557),
CLU (rs1532278), MS4A6A/4A (rs610932), ABCA7
(rs3764650) and CD33 (rs3865444) SNPs showed no
significant association with dementia in our cohort of
individuals with DS, either singly or as part of a genetic
risk score. A nominally significant association was
observed with the PICALM rs561655 variant, but the
direction of effect was opposite to that expected from
earlier studies of Alzheimer’s disease.
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t1:1 Table 1 Association between SNPs and DAD in DS
t1:2 Nearest gene SNP Risk allele Hazard ratio SE p-value
t1:3 CR1 rs3818361 A 1.10 0.17 0.59
t1:4 BIN1 rs744373 G 1.16 0.16 0.36
t1:5 CD2AP rs9349407 C 0.99 0.15 0.93
t1:6 EPHA1 rs11767557 T 1.03 0.16 0.86
t1:7 CLU rs1532278 C 1.05 0.13 0.69
t1:8 MS4A6A rs610932 G 1.03 0.15 0.83
t1:9 PICALM rs561655 A 0.67 0.14 5.89 × 10-3
t1:10 ABCA7 rs3764650 G 1.09 0.29 0.76
t1:11 CD33 rs3865444 C 0.83 0.15 0.22
t1:12 Genetic risk score - – 0.97 0.06 0.66
t1:13 Covariates included in the analyses were sex, intellectual disability and APOE genotype.
t2:1
t2:2
t2:3
t2:4
t2:5
t2:6
t2:7
t2:8
t2:9
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http://www.biomedcentral.com/1756-0500/7/42Interestingly the CR1 rs3818361 variant appeared to
be associated with premature mortality in our cohort,
particularly in the subjects without dementia. To our
knowledge, this is the first time that this variant has
been implicated as a determinant of early mortality and
the finding warrants further investigation in other cohorts
with DS.
There is considerable evidence that there is a great
deal of similarity between AD and dementia in DS [5]
and it would be reasonable to expect a similar genetic
predisposition in both conditions. A number of published
studies that have investigated the genetic predisposition to
DAD in DS and the sizes of cohorts with DS in these stud-
ies have ranged from 52 to 425 [22,30]. These studies, like
the current investigation, were underpowered to detect ef-
fect sizes of the magnitude reported for recent Alzheimer’s
disease susceptibility variants. Replication studies have
been undertaken to detect genetic variants associated with
AD using relatively large numbers of individuals with AD
and matched controls. When case control cohort sizesTable 2 Association between genetic variants and mortality
Risk allele All subjects (N = 233)*
Nearest gene SNP A Hazard ratio SE p-va
CR1 rs3818361 G 1.65 0.18 5.36 ×
BIN1 rs744373 C 1.05 0.20 0.8
CD2AP rs9349407 T 1.10 0.18 0.6
EPHA1 rs11767557 C 1.23 0.19 0.2
CLU rs1532278 G 1.17 0.16 0.3
MS4A6A rs610932 A 0.72 0.18 0.0
PICALM rs561655 G 0.71 0.17 0.0
ABCA7 rs3764650 C 1.08 0.33 0.8
CD33 rs3865444 – 0.73 0.18 0.0
Genetic risk score - 1.70 0.25 0.0
*Covariates included in the analyses were sex, intellectual disability and dementia; *were examined in three such robust studies, they have
ranged from 1829 to 3287 individuals with AD in the
general population, and 2576 to 4396 matched controls
[42-44] Given a hypothetical genetic variant associated
with DAD in DS with a HR of 1.15 and a minor allele
frequency of 0.25 (not unreasonable estimates based
upon the large Alzheimer’s disease GWAS previously
mentioned) and a ‘failure rate’ of 0.48 (the proportion of
subjects who developed dementia in the present study),
to have 80% power at an alpha of 0.05 we would need a
sample size of 4465 subjects with DS. Due to this lack of
power we cannot conclusively exclude a role for these
SNPs in DAD in DS, despite the lack of association
demonstrated in this study. It is also possible that the
lack of significant associations that we observed are due
to the fact that only one variant per locus was investigated.
The variants identified to be associated with Alzheimers’s
disease in recent GWAS are not aetiological variants [37],
the hypothesis being that they are proxies in linkage
disequilibrium with variants that exert a direct effect.Subjects with Dementia
(N = 109)**
Subjects without dementia
(N = 124)**
lue Hazard ratio SE p-value Hazard ratio SE p-value
10-3 2.33 0.29 4.08 × 10-3 1.35 0.23 0.19
2 1.34 0.44 0.51 0.94 0.25 0.81
1 1.92 0.31 0.04 0.82 0.23 0.40
9 0.76 0.35 0.44 1.47 0.24 0.10
3 0.89 0.32 0.73 1.27 0.20 0.23
7 1.02 0.34 0.95 0.64 0.21 0.03
5 0.94 0.36 0.86 0.64 0.21 0.04
1 1.27 0.54 0.65 0.74 0.46 0.52
8 0.53 0.33 0.05 0.91 0.21 0.67
3 3.13 0.52 0.03 1.54 0.28 0.13
*Covariates included in the analyses were sex and intellectual disability.
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http://www.biomedcentral.com/1756-0500/7/42It is therefore possible that by restricting our coverage
of the loci in question, we may have missed associations
with other genetic variants, due to differences in LD
patterns. Investigation of a greater number of variants
on these susceptibility loci is needed in future studies.
Clearly efforts to investigate genetic variants with small
effects on disease risk require a much larger cohort of
individuals with DS. A UK national database and DNA
resource for DS would be an invaluable resource for re-
searchers to elucidate risk alleles for DAD in DS. We
therefore recommend that all national and international
clinics with access to individuals with DS should contrib-
ute DNA samples to form DS consortia. These resources
would facilitate well-powered genome-wide genetic stud-
ies to elucidate the risk variants that contribute to DAD in
DS and investigate associations with risk variants impli-
cated in other forms of dementia.
Conclusions
Nine SNPs, previously shown to contribute to the pre-
disposition to AD, showed no association with DAD in
DS in this study. However, we cannot exclude a role for
these SNPs in DAD in DS, as our study is insufficiently
powered to pick up genetic variants with small effects
on disease.
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